NF-κB p65, IκB-α and phosphorylated IκB-α (ser 32) protein expression in the cultured human THP-1 cell line after 168 hours of hormonal treatment without or with staurosporine

<p><b>Copyright information:</b></p><p>Taken from "Sex hormone modulation of cell growth and apoptosis of the human monocytic/macrophage cell line"</p><p>Arthritis Research & Therapy 2005;7(5):R1124-R1132.</p><p>Published online 21 Jul 2005</p><p>PMCID:PMC1257440.</p><p>Copyright © 2005 Cutolo et al.; licensee BioMed Central Ltd.</p> The results are representative of four separate experiments. CNT, control; T, testosterone; E2, 17β-oestradiol

Electrophoretic mobility shift assay for NF-κB (arrow) in the cultured human THP-1 cell line

<p><b>Copyright information:</b></p><p>Taken from "Sex hormone modulation of cell growth and apoptosis of the human monocytic/macrophage cell line"</p><p>Arthritis Research & Therapy 2005;7(5):R1124-R1132.</p><p>Published online 21 Jul 2005</p><p>PMCID:PMC1257440.</p><p>Copyright © 2005 Cutolo et al.; licensee BioMed Central Ltd.</p> Electrophoretic mobility shift assay for NF-κB (arrow) in the cultured human THP-1 cell line after 168 hours of hormonal treatment and without or with staurosporine (17 nM) reveals an increased DNA binding in 17β-oestradiol (E2)-treated cells. Super shift assay for p65 (arrow) in the cells under the same conditions confirms the increased binding of p65 in E2-treated cells. The results are representative of four separate experiments. cnt, control; T, testosterone

Growth rate of the cultured human THP-1 cell line without or with 17β-oestradiol (E2) and testosterone (T), and with staurosporine after 168 hours

<p><b>Copyright information:</b></p><p>Taken from "Sex hormone modulation of cell growth and apoptosis of the human monocytic/macrophage cell line"</p><p>Arthritis Research & Therapy 2005;7(5):R1124-R1132.</p><p>Published online 21 Jul 2005</p><p>PMCID:PMC1257440.</p><p>Copyright © 2005 Cutolo et al.; licensee BioMed Central Ltd.</p> The number of recovered live cells at different times was evaluated using the methyl tetrazolium salt reduction test. Results are expressed as the mean ± standard deviation of five different experiments

The c.-201_-198delinsCTTT variant allele exhibits reduced translation potential in MCF7 cells treated with Torin1.

<p>The c.-201_-198delinsCTTT variant allele exhibits reduced translation potential in MCF7 cells treated with Torin1.</p

No impact of the <i>CDKN2A</i> 5’UTR c.-201_-198delinsCTTT variant was observed in the pGL3-promoter and in the bicistronic pRuf reporter vector as compared to the wt.

<p>The assay was performed in the pancreatic cell line BXPC-3 null for p16 ^INK4a protein.</p

Functional analysis of a CDKN2A 5’UTR germline variant associated with pancreatic cancer development - Fig 5

<p>Relative p16 ^INK4a mRNA and protein expression in c.-201_-198delinsCTTT variant, measured by qPCR (A) and Western Blot (B); for qPCR, the average normalized expression of p16^INK4a and the standard deviation of three replicates are presented. (C) Polysomal c.-201_-198delinsCTTT allelic imbalance. Cytoplasmic lysates of the lymphoblastoid cell line heterozygous for the c.-201_-198delinsCTTT variant were fractionated using 15–50% sucrose gradients and RNAs co-sedimenting with subpolysomal fractions or with polysomes were extracted and used to amplify and sequence the p16^INK4a 5’UTR by Ion Torrent. The Y-axis on the left displays the allelic coverage, while the one on the right plots the percentage of relative imbalance of the wt allele in the comparison between polysomal and subpolysomal fractions. SUB = subpolysomal; POL = polysomal; Var = c.-201_-198delinsCTTT variant.</p

The c.-201_-198delinsCTTT variant allele exhibits reduced translation potential in MCF7 cells treated with Torin1.

<p>The c.-201_-198delinsCTTT variant allele exhibits reduced translation potential in MCF7 cells treated with Torin1.</p

Dental Orthopantomography of a patient affected by NBCCS. (Patient n.11 of <b>table 2</b>).

<p>Dental Orthopantomography of a patient affected by NBCCS. (Patient n.11 of <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0043827#pone-0043827-t002" target="_blank"><b>table 2</b></a>).</p

Clinical features of NBCCS’ patients (a, d : patient n. 3; b, e : patient n.16; c: n.11 proband’s’brother; d: n. 11 proband’s father; see <b>Table 2</b>).

<p>Clinical features of NBCCS’ patients (a, d : patient n. 3; b, e : patient n.16; c: n.11 proband’s’brother; d: n. 11 proband’s father; see <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0043827#pone-0043827-t002" target="_blank"><b>Table 2</b></a>).</p

Genealogic tree of NBCCs family without the diagnosis of BCCs (Patient n.11 of <b>table 2</b>).

<p>Genealogic tree of NBCCs family without the diagnosis of BCCs (Patient n.11 of <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0043827#pone-0043827-t002" target="_blank"><b>table 2</b></a>).</p